[Basal and myoepithelial phenotype of metastatic mammary carcinomas. A prognostic factor in the palliative situation?]

Pathologe. 2008 Nov:29 Suppl 2:363-9. doi: 10.1007/s00292-008-1032-0.
[Article in German]

Abstract

Aims: The aim of the present study was to evaluate the prognostic impact of basal and myoepithelial phenotype in breast carcinomas (BBC and MBC) in the palliative situation.

Methods: Paraffin-embedded material from 244 primary breast carcinomas of patients with subsequent metastatic disease was stained immunohistochemically for CK 5/6, CK14, smooth-muscle actin, p63, estrogen receptor and progesterone receptor. BBC was defined as positive for CK5/6 and/or CK14 and MBC as positive for SMA and/or p63. Clinical and pathological data were available for all patients and follow-up data for 96.3% (range 5 days-151 months).

Results: Until the end of the follow-up period 90.2% of patients died and 6.1% are still alive. Of the tumours 28.7% could be classified as BBC and 8.2% as MBC. Kaplan Meier analysis revealed a trend for reduced survival after first diagnosis of metastasis (OASM) for BBC and MBC. Differences in survival were significant for BBC (log-rank =5.0; p=0.025), but not for MBC. CK5/6+ and CK14+ double positive tumours (n=18; 7.4%) were identified as a subgroup of BBC associated with reduced OASM (log-rank=8,6; p=0.003). This subgroup, but not BBC or MBC was an independent negative prognostic factor in a multivariate analysis including age, typing, tumour size, grading, axillary nodes, HR, Her2/neu, site of first metastasis and disease-free interval.

Conclusion: The association of BBC and MBC with reduced OASM in metastatic breast carcinomas is not independent from established prognostic factors. CK5/6+ CK14+ double positive tumours may be a subgroup of BBC with particularly unfavourable outcome.

Publication types

  • English Abstract

MeSH terms

  • Biomarkers, Tumor / analysis*
  • Breast / pathology
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / mortality
  • Breast Neoplasms / pathology*
  • Carcinoma, Ductal / drug therapy
  • Carcinoma, Ductal / mortality
  • Carcinoma, Ductal / pathology*
  • Carcinoma, Lobular / drug therapy
  • Carcinoma, Lobular / mortality
  • Carcinoma, Lobular / pathology*
  • Female
  • Humans
  • In Situ Hybridization, Fluorescence
  • Keratin-14 / analysis
  • Keratin-5 / analysis
  • Keratin-6 / analysis
  • Lymphatic Metastasis / pathology
  • Middle Aged
  • Myoepithelioma / drug therapy
  • Myoepithelioma / mortality
  • Myoepithelioma / pathology*
  • Neoplasm Recurrence, Local / drug therapy
  • Neoplasm Recurrence, Local / mortality
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Staging
  • Neoplasms, Hormone-Dependent / drug therapy
  • Neoplasms, Hormone-Dependent / pathology*
  • Neoplasms, Multiple Primary / drug therapy
  • Neoplasms, Multiple Primary / mortality
  • Neoplasms, Multiple Primary / pathology
  • Neoplasms, Second Primary / drug therapy
  • Neoplasms, Second Primary / mortality
  • Neoplasms, Second Primary / pathology
  • Palliative Care*
  • Receptors, Estrogen / analysis*
  • Receptors, Progesterone / analysis*

Substances

  • Biomarkers, Tumor
  • Keratin-14
  • Keratin-5
  • Keratin-6
  • Receptors, Estrogen
  • Receptors, Progesterone